NewsSource: EClinCloud

EClinCloud at SAPA-China 2026 | Overcoming CNS Clinical Endpoint Assessment Challenges

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Neurodegenerative diseases such as AD and PD are typically progressive and carry a heavy disease burden. As numerous clinical trials continue to advance globally, accurately identifying drug efficacy through scientifically reliable endpoint assessment has become a major challenge in CNS clinical trials.


Currently, standardizing the administration of rating scale assessments and managing their data quality are challenging, imaging assessments place high demands on standardized reading and quality control, and factors such as poor patient compliance all affect the reliability of endpoint assessment, data integrity, and the interpretability of trial results.


Against this backdrop, EClinCloud will deliver a keynote presentation at the SAPA-China 2026 Pharmaceutical Industry Conference · CNS Forum, sharing experience on the challenges and practices of endpoint assessment in CNS clinical trials.



Article illustration


Event Information

SAPA-China 2026



Presentation Information

  • EClinCloud at the Forum

    CNS Forum

  • Presentation Topic

    Pain Points and Solutions for Endpoint Assessment in Central Nervous System Disease Clinical Research

  • Presentation Time

    Friday, October 30, 2026, 9:50–10:15

  • Venue

    Heshan Hall, Suzhou Shishan International Conference Center

  • Full Agenda

Article illustration



Speaker

Article illustration



Zheng Liangyan

Medical Director, EClinCloud

Previously a chief physician in neurology with nearly 30 years of clinical diagnosis and treatment experience in neurology and extensive experience in university teaching and scientific research. Deeply engaged in clinical research, Zheng has served as a principal investigator (PI) and core research team member across multiple domestic and international multicenter clinical trials, and has completed visiting fellowships at Harvard University's McLean Hospital and the University of Siena Hospital in Italy, bringing extensive international academic exchange experience. At EClinCloud, Zheng focuses on supporting clinical research and medical operations with specialized medical expertise.



We invite you to register for the conference and connect with us on-site


WeCom screenshot _17926367759289.png

*Conference Schedule (Click to View)
























About EClinCloud


EClinCloud is a leading AI company in the clinical research industry. Driven by AI, it builds an integrated clinical intelligence cloud platform and endpoint assessment technologies, providing global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, along with scale management, linguistic validation, rater training, and data quality analysis services. By delivering efficient, precise digital solutions and leveraging AI predictive models and an intelligent data platform, EClinCloud dynamically assesses and helps improve the success rate of drug clinical trials, helping shorten drug and medical device development cycles to benefit patients.







Article illustration



























Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.